# A Study of GC101 TIL in Advanced Solid Tumors (TR)

> **NCT04967833** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Juncell Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** Tumor Infiltrating Lymphocytes (TIL)

## Key facts

- **NCT ID:** NCT04967833
- **Lead sponsor:** Shanghai Juncell Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-22
- **Primary completion:** 2025-12-22
- **Final completion:** 2026-04-22
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967833, "A Study of GC101 TIL in Advanced Solid Tumors (TR)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04967833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*